Meeder Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Meeder Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.05K	Buy	+1,970	New	+$7.61K	﹤0.01%	795

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Meeder Asset Management's RXRX Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 1,970 shares worth $6.05K. The stake represents ﹤0.01% of the portfolio and ranks #795 among its holdings.

334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Meeder Asset Management held 1,970 shares of Recursion Pharmaceuticals worth $6.05K as of Q1 2026.
Recursion Pharmaceuticals was a new Meeder Asset Management position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #795 holding.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.